Physician profile
Caleb Benjamin Stanfield
NPI 1497252225
$1,834.68
in general payments reported to CMS, 2019-2025
23 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $13.41 · 2021: $20.01 · 2022: $320 · 2023: $179 · 2024: $616 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.42 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $234.14 | 2024-2025 | Korlym |
| Amgen INC. | $233.63 | 2022-2024 | Prolia, Evenity |
| Abbott Laboratories | $207.01 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $161.59 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $147.84 | 2019 | |
| Lilly USA, LLC | $128.71 | 2022-2025 | Jardiance, Lyumjev |
| Novo Nordisk INC | $119.12 | 2020-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $87.00 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $64.96 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $64.13 | 2024-2025 | |
| Insulet Corporation | $56.61 | 2024-2025 | Omnipod |
| Becton, Dickinson and Company | $54.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.75 | 2021-2025 | Xifaxan |
| Medtronic, INC. | $43.43 | 2024 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $37.47 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $26.88 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $24.19 | 2024 | Crysvita |
| Recordati_rare_diseases_inc. | $20.55 | 2024 | Isturisa, Signifor Lar |
| Abiomed | $19.47 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2022 | |
| Evoke Pharma, INC. | $16.16 | 2024 | |
| Sequel Med Tech, LLC | $15.48 | 2025 | Twiist |
| Beta Bionics, INC. | $6.66 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Stanfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.